title: Pharmacokinetic profile of orexin A and effects on plasma insulin and glucagon in the rat.
abstract: Orexin A (OXA) is found in the central nervous system (CNS) and in the gut. Peripheral administration of OXA to rats results in an inhibition of fasting motility. Plasma OXA increases during fasting and central administration of OXA increases food intake. The aim of the present study was to assess the pharmacokinetic profile of OXA and the effect of intravenously (i.v.) administered OXA on plasma concentrations of insulin and glucagon concentrations. Rats were given OXA i.v. (100 pmol kg(-1) min(-1)) for time periods of 0, 10, 20, 30 min and for 10, 20, 30 min after ceasing a 30-min infusion. After each time period, rats were then sacrificed and blood obtained. OXA was also administered at increasing doses (0, 100, 300 and 500 pmol kg(-1) min(-1)) for 30 min and blood was obtained. Plasma OXA, insulin and glucagon levels were measured using commercially available radioimmunoassay (RIA) kits. The plasma half-life of OXA was 27.1+/-9.5 min. Stepwise increasing infusion rates of OXA confirmed a linear concentration-time curve and thus first-order kinetics. Its volume of distribution indicated no binding to peripheral tissues. Plasma glucagon decreased during infusion of OXA, while insulin was unaffected. Plasma OXA was raised fourfold after food intake. Thus, OXA has a longer plasma half-life than many other peptides found in the gut. This needs to be taken into account when assessing effects of OXA on biological parameters after peripheral administration.
authors.affiliation: Division of Surgery, Karolinska Institutet Danderyd Hospital, Stockholm SE182 88 Stockholm, Sweden. Marcus.Ehrstrom@kir.ds.sll.se
authors.forename: M
authors.initials: M
authors.lastname: Ehrström
authors.forename: E
authors.initials: E
authors.lastname: Näslund
authors.forename: F
authors.initials: F
authors.lastname: Levin
authors.forename: R
authors.initials: R
authors.lastname: Kaur
authors.forename: A L
authors.initials: AL
authors.lastname: Kirchgessner
authors.forename: E
authors.initials: E
authors.lastname: Theodorsson
authors.forename: P M
authors.initials: PM
authors.lastname: Hellström
mesh_terms: D000818:Animals; D002490:Central Nervous System / Q000378:metabolism; D005215:Fasting / Q000378:metabolism; D005934:Glucagon / Q000097:blood*; D006207:Half-Life; D007262:Infusions, Intravenous; D007328:Insulin / Q000097:blood*; D007413:Intestinal Mucosa / Q000378:metabolism; D047908:Intracellular Signaling Peptides and Proteins / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics*; D008297:Male; D009479:Neuropeptides / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics*; D000068797:Orexins; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D007328:Insulin; D047908:Intracellular Signaling Peptides and Proteins; D009479:Neuropeptides; D000068797:Orexins; D005934:Glucagon